Ligelizumab
Ligelizumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against Immunoglobulin heavy constant epsilon.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic urticaria | D000080223 | — | L50.8 | 1 | 3 | 5 | — | 1 | 10 |
| Urticaria | D014581 | EFO_0005531 | L50 | 1 | 3 | 5 | — | 1 | 10 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | 1 | 2 | — | — | 4 |
| Peanut hypersensitivity | D021183 | EFO_0007425 | — | — | 1 | 1 | — | — | 2 |
| Chronic inducible urticaria | D000094482 | — | — | — | — | 1 | — | — | 1 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 4 | — | — | — | 4 |
| Bullous pemphigoid | D010391 | EFO_0007187 | L12 | — | 1 | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 1 | — | — | — | 1 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | — | — | — | 1 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cold urticaria | D000096703 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ligelizumab |
| INN | ligelizumab |
| Description | Ligelizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | 6UQR |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109457 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | L8LE0L691T (ChemIDplus, GSRS) |
Target
Agency Approved
IGHE
IGHE
Organism
Homo sapiens
Gene name
IGHE
Gene synonyms
NCBI Gene ID
—
Protein name
Immunoglobulin heavy constant epsilon
Protein synonyms
Ig epsilon chain C region, Ig epsilon chain C region ND
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 282 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use